February 12, 2010

KidneyCasePlace

Kidneycaseplace.com is a nephrology case-based educational platform that facilitates learning via CME live events and online modules. The goal of Kidneycaseplace is to advance education in nephrology and facilitate the sharing of best practices.
document.getElementById(“post-1378-blankimage”).onload();

Leave a Comment! Posted in Educational Resource
January 11, 2010

Erythropoiesis-Stimulating Agents — Time for a Reevaluation

Unger EF, Thompson AM, Blank MJ, Temple R.   N Engl J Med.   2010 Jan 21;362(3):189-92

This NEJM “Perspectives” article from the Food and Drug Administration discusses the data driving a need to re-evaluate the use of ESAs in the treatment of anemia due to chronic kidney disease.
document.getElementById(“post-1332-blankimage”).onload();

Leave a Comment! Posted in Anemia, Editorial
January 11, 2010

Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?

Singh AK.   J Am Soc Nephrol.   2010 Jan;21(1):2-6

This editorial by Dr. Ajay Singh discusses the implications of TREAT in the context of the existing evidence base on the management of anemia due to chronic kidney disease.
document.getElementById(“post-1328-blankimage”).onload();

Leave a Comment! Posted in Anemia, Chronic Kidney Disease, Editorial
January 11, 2010

Stage IV Chronic Kidney Disease

Abboud H, Henrich WL.   N Engl J Med.   2010 Jan 7;362(1):56-65

This NEJM clinical practice article highlights the management of chronic kidney disease with a look at supporting evidence and review of formal guidelines.
document.getElementById(“post-1326-blankimage”).onload();

Leave a Comment! Posted in Chronic Kidney Disease, Review
January 11, 2010

Prehypertension: epidemiology, consequences and treatment

Pimenta E, Oparil S, Medscape.   Nat Rev Nephrol.   2010 Jan;6(1):21-30

This review of prehypertension emphasizes the importance of diagnosing this entity early as a view to preventing cardiovascular outcomes in the population as a whole and not just those patients at high-risk.
document.getElementById(“post-1324-blankimage”).onload();

Leave a Comment! Posted in Hypertension
January 11, 2010

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB.   Kidney Int.   2010 Jan;77(2):152-60

Results of two randomized trial using induction treatment with either MMF or intravenous cyclophosphamide were pooled in this article. At 24 weeks, the results show that both groups were similar with respect to percentage change in proteinuria and serum creatinine as end points when used to treat patients with class V lupus.
document.getElementById(“post-1322-blankimage”).onload();

Leave a Comment! Posted in Glomerulonephritis, Lupus
January 11, 2010

Carotid Endarterectomy Benefits Patients with CKD and Symptomatic High-Grade Stenosis

Mathew A, Eliasziw M, Devereaux PJ, Merino JG, Barnett HJ, Garg AX, North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators.   J Am Soc Nephrol.   2010 Jan;21(1):145-52

This re-analysis of data from the North American Symptomatic Carotid Endarterectomy Trial showed that patients with stage 3 CKD and symptomatic high-grade carotid stenosis gained a large benefit in stroke risk reduction after endarterectomy.
Free full text access kindly provided by the American Society of Nephrology.
document.getElementById(“post-1318-blankimage”).onload();

Leave a Comment! Posted in Chronic Kidney Disease, Vascular Disease/Calcification
January 11, 2010

Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney-Transplant Patients

Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Rostaing L.   Am J Transplant.   2010 Jan;10(1):89-98

Rituximab is being used in renal transplantation to treat donor-specific antibodies pre-transplant of acute humoral rejection post-transplant. This is a single-center retrospective study of transplant patients who received rituximab for a variety of reasons. Compared to a control group, there was an increase rate of death from infection, including unusual infections.
document.getElementById(“post-1316-blankimage”).onload();

Leave a Comment! Posted in Renal Transplantation
January 11, 2010

Asymmetrical Dimethylarginine Is Associated with Renal and Cardiovascular Outcomes and All-cause Mortality in Renal Transplant Recipients

Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, Jardine A, Holdaas H.   Kidney Int.   2010 Jan;77(1):44-50

ADMA is a known risk factor for mortality and cardiovascular events in the CKD and ESRD populations. This study found that transplant recipients with higher levels of ADMA were at an increased risk of graft failure, cardiovascular events and death. Whether therapeutic interventions that lower ADMA levels would decrease the risk of death is unknown.
document.getElementById(“post-1314-blankimage”).onload();

Leave a Comment! Posted in Renal Transplantation
January 11, 2010

Morbidity and Mortality in 1022 Consecutive Living Donor Nephrectomies: Benefits of a Living Donor Registry

Lightfoot JT, Hilton F Jr, Fortney SM.   Aviat Space Environ Med.   1991 Jan;62(1):19-25

Quantifying the risks of living donation is important information for potential living donors and members of the transplant team. This registry includes all donors over a 12-year period. Major postoperative complications occurred in 3% of patients, while minor complications, mostly UTIs, occurred in 18%. There were no deaths.
document.getElementById(“post-1311-blankimage”).onload();

Leave a Comment! Posted in Renal Transplantation
January 11, 2010

Effect of Hemodialysis before Transplant Surgery on Renal Allograft Function – A Pair of Randomized Controlled Trials

Kikić Z, Lorenz M, Sunder-Plassmann G, Schillinger M, Regele H, Györi G, Mühlbacher F, Winkelmayer WC, Böhmig GA.   Transplantation.   2009 Dec 27;88(12):1377-85

Previous studies have suggested that hemodialysis immediately before transplant surgery may increase the risk of delayed graft function. In this RCT, patients were randomized to be dialyzed or not pre-transplant; patients with a potassium > 5.0 were randomized to citrate or heparin
anticoagulation. There were no differences in the incidence of DGF, acute rejection or early [...]

Leave a Comment! Posted in Hemodialysis, Renal Transplantation
December 14, 2009

Contraindicated Medication Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention

Tsai TT, Maddox TM, Roe MT, Dai D, Alexander KP, Ho PM, Messenger JC, Nallamothu BK, Peterson ED, Rumsfeld JS, National Cardiovascular Data Registry.   JAMA.   2009 Dec 9;302(22):2458-64

This observational study identified that patients with renal failure undergoing PCI (percutaneous coronary intervention) frequently receive contraindicated anticoagulants such as enoxaparin and eptifibatide.  Such exposure was associated with an increased risk of in-hospital major bleeding.
document.getElementById(“post-1303-blankimage”).onload();

Leave a Comment! Posted in Internal Medicine for Nephrologists, Vascular Disease/Calcification
December 14, 2009

Home Hemodialysis, Daily Hemodialysis, and Nocturnal Hemodialysis: Core Curriculum 2009

Perl J, Chan CT.   Am J Kidney Dis.   2009 Dec;54(6):1171-84

This next addition to the AJKD Core Curriculum series provides a detailed overview of the topic of “Home Hemodialysis, Daily Hemodialysis and Nocturnal Hemodialysis”.
document.getElementById(“post-1301-blankimage”).onload();

Leave a Comment! Posted in Educational Resource, Hemodialysis
Get Adobe Flash playerPlugin by wpburn.com wordpress themes